Study of therapy with zoledronic acid in prostate cancer patients with bone metastases.
Not Applicable
Recruiting
- Conditions
- Prostate Cancer
- Registration Number
- JPRN-UMIN000011442
- Lead Sponsor
- Osaka University Graduate School of Medicine,Department of Organ Specific Regulation (Urology)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients who have contraindications to zoledronic acid. 2)Patients without improvement of surgical wounds after invasive dental treatment. 3)Patients who have previously received zoledronic acid or denosumab. 4)Serum creatinine: more than 3.0mg/dL 5) Patient judged inappropriate for this study by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Skeletal related events incidence
- Secondary Outcome Measures
Name Time Method Search for risk factors of SREs (bone turnover markers, patient characteristics, PSA, bone pain, etc.) Adverse events